Navigation Links
Mylan Announces Change in Board Leadership
Date:5/7/2009

- Co-founder Mike Puskar retires as Chairman of the Board -

- Robert J. Coury elected Chairman of the Board -

PITTSBURGH May 7 /PRNewswire-FirstCall/ -- Mylan Inc. (Nasdaq: MYL) today announced a change in leadership to its Board of Directors. Mylan co-founder and chairman Milan ("Mike") Puskar announced that he is stepping down as Chairman of the Board effective immediately and that he will retire as a director effective Oct. 1. The board subsequently elected Mylan's Vice Chairman and CEO Robert J. Coury to succeed Puskar as Chairman of the Board.

Upon his election Coury stated: "On behalf of the Board of Directors and all of Mylan's employees and shareholders, I would like to personally thank Mike Puskar for his many accomplishments; his impact on the industry; and for his service and leadership. Mike will truly, truly be missed."

Coury continued, "I am also extremely honored to add the chairman role to my current responsibilities as Chief Executive Officer of Mylan. At this time, I would also like to announce that Rod Piatt, who has served as a member of our Board of Directors for the past five years, has been appointed Vice Chairman of the Board of Directors."

Puskar co-founded Mylan as a privately held drug distributor with Don Panoz in 1961. He has been a director of the company for the past 33 years, serving as its chairman since 1993. Puskar also was the company's president from 1976 to 2000 and CEO from 2000 until 2002. His tenure has been marked by a steady and strong leadership position among generic pharmaceuticals companies in the U.S. As one of the industry's pioneers, Puskar built a legacy on quality manufacturing, unparalleled customer service and policy leadership.

Puskar commented: "The time has come for me to step down as chairman, and I am more than confident that under Robert's passionate and strategic direction, Mylan will continue to provide leadership for an industry that is continually evolving. Robert has taken what we started almost 50 years ago and turned it into a global powerhouse with a vast reach that is unique among our peers. I would like to congratulate him on his remarkable accomplishments to date, and I wish him all the best as he executes on his vision for the next 50 years."

Coury has been Mylan's Vice Chairman and CEO since 2002 and had previously served as a consultant to the company from 1995 to 2002. Under his leadership and strategic direction, the company transformed from the third largest generics company in the U.S. to the third largest generics and specialty pharmaceutical company in the world with the 2007 game-changing acquisitions of a majority interest in Matrix Laboratories and the global generics business of Merck KGaA. Prior to joining Mylan, Coury was the principal of Coury Consulting L.P., a corporate strategy advisory firm he formed in 1989 in Pittsburgh.

Piatt was elected to Mylan's board in 2004. He is a current member of the board's audit, finance, compensation and governance, and nominating committees. Piatt is the president and owner of Horizon Properties, a real estate development company he founded in 1996 as well as CEO and Director of Lincoln Manufacturing Inc., a steel and coal manufacturing company.

Mylan Inc., which provides products to customers in more than 140 countries and territories, ranks among the leading diversified generics and specialty pharmaceutical companies in the world. The company maintains one of the industry's broadest - and highest quality - product portfolios, supported by a robust product pipeline; owns a controlling interest in the world's third largest active pharmaceutical ingredient manufacturer; and operates a specialty business focused on respiratory and allergy therapies. For more information, please visit www.mylan.com.


'/>"/>
SOURCE Mylan Inc.
Copyright©2009 PR Newswire.
All rights reserved

Related medicine news :

1. Mylan Commences Tender Offers and Consent Solicitations for Its 5.750% Senior Notes Due 2010 and 6.375% Senior Notes Due 2015 in Connection With Its Proposed Acquisition of Mercks Generic Pharmaceutical Business
2. Mylan Announces Final FDA Approval for Carvedilol Tablets
3. Mylan Announces Tentative FDA Approval for Topiramate Capsules
4. Mylan Announces Appointment of M. Fabiana Lacerca as Senior Vice President and Chief Compliance Officer
5. Mylan Announces Extension of Tender Offers for Its 5.750% Senior Notes due 2010 and 6.375% Senior Notes due 2015
6. Mylan Announces Appointment of David A. Lillback as Senior Vice President and Global Head of Human Resources
7. Mylan Announces Appointment of Brian Byala as Senior Vice President and Treasurer
8. Mylan Announces Appointment of Didier Barret as President, Europe, Middle East and Africa
9. Mylan Announces Appointment of Harry A. Korman as President, North America
10. Mylan Announces Appointment of John Montgomery as President, Asia Pacific
11. Mylan Announces Management of Specialty Business, Dey L.P.
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:6/25/2016)... ... ... closing of Bruton Memorial Library on June 21 due to a possible lice infestation, as ... of head lice: the parasite’s ability to live away from a human host, and to ... one in the event that lice have simply gotten out of control. , As lice ...
(Date:6/25/2016)... ... , ... On Friday, June 10, Van Mitchell, Secretary of the Maryland Department ... in recognition of their exemplary accomplishments in worksite health promotion. , The Wellness at ... Wellness Symposium at the BWI Marriott in Linthicum Heights. iHire was one of 42 ...
(Date:6/24/2016)... CA (PRWEB) , ... June 24, 2016 , ... Marcy was in a crisis. Her ... would lash out at his family verbally and physically. , “When something upset him, he ... he would use it. He would throw rocks at my other children and say he ...
(Date:6/24/2016)... ... ... Inc, makers of Topricin and MyPainAway Pain Relief Products, join The ‘Business for a Fair ... hour by 2020 and then adjusting it yearly to increase at the same rate as ... the wage floor does not erode again, and make future increases more predictable. , The ...
(Date:6/24/2016)... ... 2016 , ... Strategic Capital Partners, LLC (SCP) in concert ... capital for emerging technology companies. SCP has delivered investment events and professional ... than a million dollars of capital investment for five companies. The ...
Breaking Medicine News(10 mins):
(Date:6/24/2016)... , June 24, 2016   Pulmatrix, Inc ... company developing innovative inhaled drugs, announced today that it ... Russell Investments reconstituted its comprehensive set of U.S. ... "This is an important milestone for Pulmatrix," said ... increase shareholder awareness of our progress in developing drugs ...
(Date:6/23/2016)... 23, 2016 Any dentist who has made an ... current process. Many of them do not even offer this ... and high laboratory costs involved. And those who ARE able ... such a high cost that the majority of today,s patients ... Parsa Zadeh , founder of Dental Evolutions Inc. and ...
(Date:6/23/2016)... 2016 Capricor Therapeutics, Inc. ... biotechnology company focused on the discovery, development and ... enrollment in its ongoing randomized HOPE-Duchenne clinical trial ... of its 24-patient target. Capricor expects the trial ... of 2016, and to report top line data ...
Breaking Medicine Technology: